Within  weeks prior to registration: Subject has prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) test =< . x the laboratory upper limit of normal (ULN)
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< . x upper limit of normal (ULN); subjects receiving anticoagulation treatment may be allowed to participate with INR established within the therapeutic range prior to randomization
Prothrombin time (PT)/international normalized ratio (INR)* =< . x upper limit of normal (ULN)\r\n* Subjects receiving anticoagulation treatment may be allowed to participate with INR established within the therapeutic range prior to randomization; PT and partial thromboplastin time (PTT) > . x ULN are permitted in these subjects
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) < . x upper limit of normal (ULN)
Prothrombin time (PT) such that international normalized ratio (INR) is =< . (or an in-range INR, usually between  and , if a patient is on a stable dose of therapeutic warfarin and a partial thromboplastin time (PTT) =< upper limit of normal
Adequate Coagulation defined as prothrombin time (PT) and partial thromboplastin time (PTT) <= . x upper limit of normal and an international normalized ratio (INR) <= ..
Prothrombin time (PT)/international normalized ratio (INR)/partial thromboplastin time (PTT) =< . x upper limit of normal (ULN) (for patients on warfarin, INR should be maintained within therapeutic limits (either - or .-. for heart valve patients)
The patient has adequate coagulation: prothrombin time (PT) and an International Normalized Ratio (INR), and partial thromboplastin time (PTT) ? . times the upper limit of normal (ULN),
Prothrombin time (PT) or international normalized ratio (INR) and a partial thromboplastin time (PTT) > . times the upper limit of normal
Prothrombin time (PT)/ international normalized ratio (INR), partial thromboplastin time (PTT) < . x upper limit of normal (ULN)
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) < . x upper limit of normal (ULN).
Prothrombin time (PT)/institutional normalized ratio (INR) and partial thromboplastin time (PTT) =< . x upper limit of normal (ULN)
The subject has prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test >= . x the laboratory upper limit of normal (ULN) within  days before the first dose of study treatment
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< . x institutional upper limit of normal; subjects receiving anticoagulation treatment may be allowed to participate with INR established within the therapeutic range prior to alternate assignment
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< . x upper limit of normal (ULN)
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< . X upper limit of normal (ULN)
Prothrombin time (PT)/international normalized ratio (INR) < . x upper limit of normal (ULN) and partial thromboplastin time (PTT) (activated PTT [aPTT]) < . x ULN
International normalized ratio (INR) =< . or prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits (WNL) of the institution
Blood coagulation parameters: prothrombin time (PT) such that international normalized ratio (INR) is =< . (or an in-range INR, usually between  and , if a subject is on a stable dose of therapeutic warfarin or anticoagulants for management of venous thrombosis including pulmonary thrombo-embolus) and a partial thromboplastin time (PTT) =< . times the upper limit of normal
Prothrombin time/international normalized ratio (PT/INR) and partial thromboplastin time (PTT) =< . x upper limit of normal (ULN)
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< . x upper limit of normal (ULN)
Prothrombin time (PT) or partial thromboplastin time (PTT) < . x upper limit of normal (ULN), OR international normalized ratio (INR) < .
Prothrombin time (PT) such that international normalized ratio (INR) is less than or equal to . x ULN (or an in range INR, usually between  and , if a patient is on a stable dose of therapeutic warfarin) and a partial thromboplastin time (PTT) less than or equal to . times the upper limit of normal
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< . x upper limit of normal (ULN) unless using warfarin for therapeutic anti-coagulation
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< . x institutional upper limit of normal (IULN) (subjects on Coumadin are included if their coagulation is within a normal therapeutic range)
Prothrombin time (PT)/international normalized ratio (INR)/partial thromboplastin time (PTT) within . x the upper limit of normal within  days prior to registration unless the patient is receiving coumadin and has a stable INR that is in range for the desired level of anticoagulation
Prothrombin time (PT)/partial thromboplastin time (PTT)/international normalized ratio (INR) =< . upper limit of normal (ULN)
Prothrombin time (PT), partial thromboplastin time (PTT) and international normalized ratio (INR) =< . upper limit of normal (ULN)
Normal prothrombin time (PT)/international normalized ratio (INR) and partial prothrombin time (PTT)
Prothrombin time (PT) such that international normalized ratio (INR) is =< . and a partial thromboplastin time (PTT) =< . time the upper limit of normal unless the patient is therapeutically anti-coagulated for history of cancer-related thrombosis and has stable coagulation parameters
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< . x institutional upper limit of normal
Prothrombin time (PT) or partial thromboplastin time (PTT) < . x upper limit of normal (ULN), OR international normalized ratio (INR) < .
Prothrombin time/international normalized ratio (INR) and partial thromboplastin time within normal limits
Prothrombin time (PT) or international normalized ratio (INR), and partial thromboplastin time (PTT) =< . x upper limit of normal unless patient is receiving anticoagulants; if patient is on warfarin therapy, levels should be within therapeutic range
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< . X upper limit of normal (ULN)
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< . x institutional upper limit of normal (ULN)
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< . x institutional ULN; subjects receiving anticoagulation treatment may be allowed to participate with INR established within the therapeutic range prior to randomization\r\n* NOTE: this applies to patient in the normal and renal dysfunction cohorts (N, R and R); elevated PT/INR is allowed for patients in the liver dysfunction cohorts
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< . x upper limit of normal (ULN) (Note: subjects receiving anticoagulation treatment may enroll with INR established within the therapeutic range prior to day  [D] of treatment)
The patient has an adequate coagulation function as defined by international normalized ratio (INR) =< . x upper limit of normal (ULN) or prothrombin time (PT) =< . x ULN, and partial thromboplastin time (PTT or aPTT) =< . x ULN (those receiving anticoagulation therapy except low molecular weight heparin are excluded) within  days prior to registration
active, uncorrected bleeding disorder as determined by abnormal prothrombin time, partial thromboplastin time, or INR at the time of HIFU (use international lab normal ranges for parameters);
Patients must have baseline prothrombin time (PT)/international normalized ratio (INR) <  x institutional upper limit of normal and partial thromboplastin time (PTT) <  x ULN within  days of initiating the induction cycle; (for patients with coagulation abnormalities that are correctable, coagulation factor support per institutional standard of care for AML is allowed)
Prothrombin time (PT)/partial thromboplastin time (PTT)/international normalized ratio (INR) =< . upper limit of normal (ULN)
International normalized ratio (INR) < . or a prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits; patients receiving anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) < . upper limit of normal (ULN)
Prothrombin time (PT) or international normalized ratio (INR), and partial thromboplastin time (PTT) =< . x upper limit of normal unless subject is receiving anticoagulants; if the subject is on anticoagulation therapy, levels should be within therapeutic range
The subject has prothrombin time/international normalized ratio (PT/INR) or partial thromboplastin time (PTT) test results at screening >= . x the laboratory upper limit of normal
Patients must have prothrombin time (PT)/international normalized ratio (INR)/partial thromboplastin time (PTT) within . x the upper limit of normal
Prothrombin time (PT) and partial thromboplastin time (PTT) ? . x the upper limit of normal (ULN) unless receiving anticoagulation therapy. If receiving anticoagulation therapy, eligibility will be based upon International Normalization Ratio (INR)
Prothrombin time (PT) or international normalized ratio (INR) and partial thromboplastin time (PTT) < . X upper limit of normal (ULN)
Evidence of bleeding diathesis or coagulopathy (partial thromboplastin time [PTT] and/or either prothrombin time [PT] or international normalized ratio [INR] > . x upper limit of normal) (except for subjects receiving anti-coagulation therapy); concurrent use of Coumadin or warfarin will be acceptable and monitoring patients on warfarin or Coumadin will follow the standard of care as dictated by the prescribing physician (PT/PTT); if the prescribing physician is not a Moffitt medical doctor (MD), then the prescribing MD will be notified by the research staff of the subject participating in the study, and monitors for PT, PTT will be obtained from patient during the  month study visit for review
Prior anticoagulant therapy use is allowed provided therapy is discontinued at least  days prior to the breast biopsy in order to reduce the risk of bleeding. For participants who have taken an anticoagulation within the past  days, international normalized ratio must be ? . x institutional upper limit of normal and prothrombin time and partial thromboplastin time ? ULN prior to the breast biopsy.
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< . times institutional upper limit of normal
Prothrombin time (PT)/international normalized ratio (INR)/partial thromboplastin time (PTT) (activated [a]PTT) < . x institutional upper limit of normal (within  days of study registration)
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< . X upper limit of normal (ULN)
The patient has adequate coagulation: prothrombin time (PT), partial thromboplastin time (PTT), and an International Normalized Ratio within normal limits.
